Fortrea Holdings (FTRE) Non-Current Debt (2023 - 2026)
Fortrea Holdings' (FTRE) quarterly Non-Current Debt came in at $1.0 billion in Q2 2026, down 5.79% YoY from $1.1 billion in Q2 2025, and down 0.52% on a QoQ basis from $1.0 billion in Q1 2026.
Fortrea Holdings (FTRE) Non-Current Debt (2023 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 4 years of Non-Current Debt data on file, last reported at $1.0 billion in Q2 2026.
- Quarterly Non-Current Debt fell 5.79% year-over-year to $1.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.0 billion (down 5.79% YoY) and the FY2025 annual result came in at $1.0 billion, changed 0.16% from the prior year.
- Non-Current Debt declined to $1.0 billion in Q2 2026, from $1.0 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.6 billion in Q2 2023 to a low of $1.0 billion in Q2 2026.
- A 4-year average of $1.2 billion and a median of $1.1 billion in 2025 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt slumped 32.97% — and 2025, when it declined 0.16%.
- Tracing FTRE's Non-Current Debt over 4 years: stood at $1.6 billion in 2023, then slumped by 32.97% to $1.0 billion in 2024, then dropped by 0.16% to $1.0 billion in 2025, then decreased by 1.03% to $1.0 billion in 2026.
- The last three Non-Current Debt figures came in at $1.0 billion (Q2 2026), $1.0 billion (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 1.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Bn |
| Mar 31, 2026 | 1.04 Bn |
| Dec 31, 2025 | 1.05 Bn |
| Sep 30, 2025 | 1.05 Bn |
| Jun 30, 2025 | 1.10 Bn |
| Mar 31, 2025 | 1.05 Bn |
| Dec 31, 2024 | 1.05 Bn |
| Sep 30, 2024 | 1.12 Bn |
| Jun 30, 2024 | 1.12 Bn |
| Mar 31, 2024 | 1.56 Bn |
| Dec 31, 2023 | 1.57 Bn |
| Sep 30, 2023 | 1.57 Bn |
| Jun 30, 2023 | 1.58 Bn |